Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Efficacy of Human-simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-lactamase-producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model.

Asempa TE, Motos A, Abdelraouf K, Bissantz C, Zampaloni C, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02382-18. doi: 10.1128/AAC.02382-18. [Epub ahead of print]

PMID:
30670411
2.
3.

In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model.

Almarzoky Abuhussain SS, Avery LM, Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01931-18. doi: 10.1128/AAC.01931-18. Print 2019 Jan.

PMID:
30373797
4.

Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.

Avery LM, Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00948-18. doi: 10.1128/AAC.00948-18. Print 2018 Nov.

PMID:
30181365
5.

Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model.

Kidd JM, Abdelraouf K, Asempa TE, Humphries RM, Nicolau DP.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00506-18. doi: 10.1128/AAC.00506-18. Print 2018 Oct.

PMID:
30012755
6.

Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model.

Stainton SM, Abdelraouf K, Utley L, Pucci MJ, Lister T, Nicolau DP.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00239-18. doi: 10.1128/AAC.00239-18. Print 2018 Jul.

7.

In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model.

Abdelraouf K, Kim A, Krause KM, Nicolau DP.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e01074-18. doi: 10.1128/AAC.01074-18. Print 2018 Aug.

8.

Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.

Abdelraouf K, Linder KE, Nailor MD, Nicolau DP.

Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):705-714. doi: 10.1080/17425255.2017.1329417. Epub 2017 May 19. Review.

PMID:
28486001
9.

Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.

Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01957-16. doi: 10.1128/AAC.01957-16. Print 2017 Jan.

10.

Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies.

Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H.

Breast Cancer (Auckl). 2015 Sep 27;9(Suppl 2):17-34. doi: 10.4137/BCBCR.S29420. eCollection 2015. Review.

11.

Reply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?".

Abdelraouf K, Tam VH.

Antimicrob Agents Chemother. 2014 Oct;58(10):6339. doi: 10.1128/AAC.03784-14. No abstract available.

12.

Uptake of polymyxin B into renal cells.

Abdelraouf K, Chang KT, Yin T, Hu M, Tam VH.

Antimicrob Agents Chemother. 2014 Jul;58(7):4200-2. doi: 10.1128/AAC.02557-14. Epub 2014 Apr 14.

13.

Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.

He J, Abdelraouf K, Ledesma KR, Chow DS, Tam VH.

Int J Antimicrob Agents. 2013 Dec;42(6):559-64. doi: 10.1016/j.ijantimicag.2013.07.009. Epub 2013 Aug 22.

14.

Pharmacokinetics and renal disposition of polymyxin B in an animal model.

Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH.

Antimicrob Agents Chemother. 2012 Nov;56(11):5724-7. doi: 10.1128/AAC.01333-12. Epub 2012 Aug 20.

15.

Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.

Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH.

Antimicrob Agents Chemother. 2012 Sep;56(9):4625-9. doi: 10.1128/AAC.00280-12. Epub 2012 Jun 11.

16.

Predicting bacterial fitness cost associated with drug resistance.

Guo B, Abdelraouf K, Ledesma KR, Nikolaou M, Tam VH.

J Antimicrob Chemother. 2012 Apr;67(4):928-32. doi: 10.1093/jac/dkr560. Epub 2012 Jan 9.

PMID:
22232512
17.

Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model.

Guo B, Abdelraouf K, Ledesma KR, Chang KT, Nikolaou M, Tam VH.

Antimicrob Agents Chemother. 2011 Oct;55(10):4601-5. doi: 10.1128/AAC.00508-11. Epub 2011 Aug 1.

18.

Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report.

Kwa AL, Abdelraouf K, Low JG, Tam VH.

Clin Infect Dis. 2011 May;52(10):1280-1. doi: 10.1093/cid/cir137. No abstract available.

19.

Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa.

Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH.

J Antimicrob Chemother. 2011 Jun;66(6):1311-7. doi: 10.1093/jac/dkr105. Epub 2011 Mar 17.

PMID:
21415038
20.

Pharmacokinetics of polymyxin B in an infant with multidrug-resistant Klebsiella pneumoniae bacteremia.

Salvatore CM, Abdelraouf K, Hsing DD, Tam VH.

Pediatr Infect Dis J. 2011 Jun;30(6):537-9. doi: 10.1097/INF.0b013e318207a7c1.

PMID:
21164382
21.

Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.

Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro JP, Garey KW.

Antimicrob Agents Chemother. 2010 Mar;54(3):1160-4. doi: 10.1128/AAC.01446-09. Epub 2010 Jan 19.

Supplemental Content

Loading ...
Support Center